A new study led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is shedding light on a novel role of breast cancer gene 1 (BRCA1) in tumor suppression.
Prognosis and survival evaluation in treating high-risk BRAF V600 mutation stage III or IV melanoma with dabrafenib plus trametinib therapy: A meta-analysis of 2,660 patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results